Frier Levitt Life Sciences attorneys, Dae Y. Lee, Pharm.D., Esq., CPBS and Jonathan Levitt, Esq. co-authored an article titled: “The Consolidated Appropriations Act and PBM Transparency” in Pharmaceutical Executive on May 12, 2023.
In this article, Dae and Jon explore how the Consolidated Appropriations Act (CAA) introduces significant changes in the design of pharmacy benefit plans with aims to level the playing field between PBMs and their employee healthcare benefit plan clients. This new federal law brings unprecedented transparency to the complex realm of PBMs, unraveling the intricacies of drug pricing and rebates. As Jonathan stated at his testimony before the U.S. Senate Committee on Finance during its hearing titled “Pharmacy Benefit Managers and the Prescription Drug Supply Chain: Impact on Patients and Taxpayers,” there needs to be more transparency with PBM business practices. This legislation represents a crucial stride toward empowering patients and fostering improved healthcare affordability.
Read the full article here.
To view Jonathan’s opening statement of his testimony, click here.
